<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00219102</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2310</org_study_id>
    <nct_id>NCT00219102</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate Safety &amp; Efficacy of the Combination of Aliskiren, Valsartan &amp; Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients</brief_title>
  <official_title>A 12-week, Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy &amp; Safety of Aliskiren in Patients With Diabetes &amp; Hypertension Not Adequately Responsive to the Combination of Valsartan 160 mg &amp; Hydrochlorothiazide 25 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      To evaluate the blood pressure lowering effect and safety of aliskiren used in combination
      with valsartan/hydrochlorothiazide in diabetic patients with essential hypertension, not
      adequately responsive to the combination of valsartan and hydrochlorothiazide
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in diastolic blood pressure after 12 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic blood pressure after 12 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic and diastolic blood pressure after 6 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure of &lt; 80 mmHg or a reduction from baseline of diastolic blood pressure of &gt; 10 mmHg after 12 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achieve mean sitting blood pressure control target of &lt; 130/80 mmHg after 12 weeks</measure>
  </secondary_outcome>
  <enrollment>336</enrollment>
  <condition>Hypertension</condition>
  <condition>Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aliskiren</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients with essential hypertension

          -  Patients with a documented diagnosis of Type 1 or Type 2 diabetes mellitus.

          -  Patients who are eligible and able to participate in the study

        Exclusion Criteria

          -  Severe hypertension

          -  Uncontrolled diabetes type I and II

          -  History or evidence of a secondary form of hypertension

          -  History of Hypertensive encephalopathy or cerebrovascular accident.

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Salisbury,</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>February 24, 2011</last_update_submitted>
  <last_update_submitted_qc>February 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2011</last_update_posted>
  <keyword>Hypertension,</keyword>
  <keyword>diabetes,</keyword>
  <keyword>aliskiren,</keyword>
  <keyword>blood pressure,</keyword>
  <keyword>valsartan,</keyword>
  <keyword>hydrochlorothiazide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

